A REVIEW ON AGENTS FOR THE TREATMENT OF LEPROSY INFECTION
Leprosy is an ancient disease which is caused due to bacterial infection while curable but endures to be a substantial health problem in numerous parts across the world. It is an extremely contagious disease that is caused by any of 3 strains of bacteria such as Mycobacterium tuberculosis; Nontuberculous Mycobacterium; and Mycobacterium leprae. In several regions of Brazil, leprosy is a health issue which is still an endemic. Mainly skin, peripheral nerves, eyes, and mucosa of the upper respiratory tract are affected due to this chronic infection. As per the data shared by WHO across 159 countries globally, there were around 208,619 new leprosy cases reported. The global prevalence of leprosy is overcome with the aid of multidrug therapy which remains to be the chiefly targeted for treatment. The multidrug therapy gets attention as they show tremendous potential in fighting this disease. This review briefs about the different drugs and strategies which are used in treatment and superintendence of leprosy.
2. Agrawal A. Clinical management of leprosy reactions. Infect Dis Clin Pract 2010;18:230.
3. Antunes DE, Araujo S, Ferreira GP, Cunha AC, Costa AV, Gonçalves MA, et al. Identification of clinical, epidemiological and laboratory risk factors for leprosy reactions during and after multidrug therapy. Mem Inst Oswaldo Cruz 2013;108:901-8.
4. Avanzi C, Singh P, Truman RW, Suffys PN. Molecular epidemiology of leprosy: An update. Infect Genet Evol 2020;86:104581.
5. Bennett BH, Parker DL, Robson M. Leprosy: Steps along the journey of eradication. Public Health Rep 2008;123:198-205.
6. Bharadwaj M. Revalidation of various clinical criteria for the classification of leprosy-a clinic-pathological study. Lepr Rev 2012;83:354-62.
7. Tortoli E. Microbiological features and clinical relevance of new species of the genus Mycobacterium. Clin Microbiol Rev 2014;27:727-52.
8. Bhat RM, Prakash C. Leprosy: An overview of pathophysiology. Interdiscip Perspect Infect Dis 2012;2012:181089.
9. Bhide AA, Khemani UN, Kamath RR, Vaidyanathan V, Ponathil AP, Kura MM. An alternative hepatosafe treatment in leprosy. Indian J Drugs Dermatol 2016;2:33.
10. Bratschi MW, Steinmann P, Wickenden A, Gillis TP. Current knowledge on Mycobacterium leprae transmission: A systematic literature review. Lepr Rev 2015;86:142-55.
11. Bremner JB, Ambrus JI, Samosorn S. Dual action-based approaches to antibacterial agents. Curr Med Chem 2007;4:1459-77.
12. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 2001;104:901-2.
13. Cavazzuti A, Paglietti G, Hunter WN, Gamarro F, Piras S, Loriga M, et al. Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development. Proc Natl Acad Sci USA 2008;105:1448-53.
14. Cortela DC, de Souza AL Jr., Virmond MC, Ignotti E. Inflammatory mediators of leprosy reactional episodes and dental infections: A systematic review. Mediators Inflamm 2015;2015:548540.
15. Costa PD, Fraga LR, Kowalski TW, Daxbacher EL, Schuler-Faccini L, Vianna FS. Erythema nodosum leprosum: Update and challenges on the treatment of a neglected condition. Acta Trop 2018;183:134-41.
16. Dacso MM, Jacobson RR, Scollard DM, Stryjewska BM, Prestigiacomo JF. Evaluation of multi-drug therapy for leprosy in the United States using daily rifampin. South Med J 2011;104:689-94.
17. de Souza Aarão TL, Esteves NR, Esteves N, de Miranda Soares LP, da Silva Pinto D, Fuzii HT, et al. Relationship between growth factors and its implication in the pathogenesis of leprosy. Microb Pathog 2014;77:66-72.
18. Degang Y, Akama T, Hara T, Tanigawa K, Ishido Y, Gidoh M, et al. Clofazimine modulates the expression of lipid metabolism proteins in Mycobacterium leprae-infected macrophages. PLoS Negl Trop Dis 2012;6:e1936.
19. El Idrissi NB, Das PK, Fluiter K, Rosa PS, Vreijling J, Troost D, et al. Leprae components induce nerve damage by complement activation: Identification of lipoarabinomannan as the dominant complement activator. Acta Neuropathol 2015;129:653-67.
20. Fischer M. Leprosy-an overview of clinical features, diagnosis, and treatment. J Dtsch Dermatol Ges 2017;15:801-27.
21. Gaschignard J, Grant AV, Thuc NV, Orlova M, Cobat A, Huong NT, et al. Pauci-and multibacillary leprosy: Two Distinct, genetically neglected diseases. PLoS Negl Trop Dis 2016;10:e0004345.
22. Gautam VP. Treatment of leprosy in India. J Postgrad Med 2009;55:220-4.
23. Gelber RH, Grosset J. The chemotherapy of leprosy: An interpretive history. Lepr Rev 2012;83:221-40.
24. Graham A, Furlong S, Margoles LM, Owusu K, Franco-Paredes C. Clinical management of leprosy reactions. Infect Dis Clin Pract 2010;18:235-8.
25. Gupta SK. Histoid leprosy: A review of the literature. Int J Dermatol 2015;54:1283-8.
26. Parkash O. Classification of leprosy into multibacillary and paucibacillary groups: An analysis. FEMS Immunol Med Microbiol 2009;55:1-5.
27. Aarao TL, de Sousa JR, Falcao AS, Falcao LF, Quaresma JA. Nerve growth factor and pathogenesis of leprosy: Review and update. Front Immunol 2018;9:939.
28. Polycarpou A, Walker SL, Lockwood DN. New findings in the pathogenesis of leprosy and implications for the management of leprosy. Curr Opin Infect Dis 2013;26:413-9.
29. Gutierrez MC, Supply P, Brosch R. Pathogenomics of mycobacteria. In: Microbial Pathogenomics. Vol. 6. Germany: Karger; 2009. p. 198-210.
30. Hevener KE, Yun MK, Qi J, Kerr ID, Babaoglu K, Hurdle JG, Lee RE. Structural studies of pterin-based inhibitors of dihydropteroate synthase. J Med Chem 2010;53:166-77.
31. Honap TP, Pfister LA, Housman G, Mills S, Tarara RP, Suzuki K, et al. Mycobacterium leprae genomes from naturally infected nonhuman primates. PLoS Negl Trop Dis 2018;12:e0006190.
32. Hwang TJ, Dotsenko S, Jafarov A, Weyer K, Falzon D, Lunte K, et al. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: Analysis of published guidance and meta-analysis of cohort studies. BMJ Open 2014;4:e004143.
33. Ishii N. Recent advances in the treatment of leprosy. Dermatol Online J 2003;9:5.
34. Jyothi P, Riyaz N, Nandakumar G, Binitha MP. A study of oxidative stress in paucibacillary and multibacillary leprosy. Indian J Dermatol Venereol Leprol 2008;74:80.
35. Kahawita IP, Lockwood DN. Towards understanding the pathology of erythema nodosum leprosum. Trans R Soc Trop Med Hyg 2008;102:329-37.
36. Kamath S, Vaccaro SA, Rea TH, Ochoa MT. Recognizing and managing the immunologic reactions in leprosy. J Am Acad Dermatol 2014;71:795-803.
37. Pfyffer GE. Mycobacterium: General characteristics, laboratory detection, and staining procedures. In: Manual of Clinical Microbiology. Washington, DC: ASM Press; 2015. p. 536-69.
38. Prasad PV, Kaviarasan PK. Leprosy therapy, past and present: Can we hope to eliminate it. Indian J Dermatol 2010;55:316-24.
39. Prasad PV, Babu A, Kaviarasan PK, Viswanathan P, Tippoo R. MDT-MB therapy in paucibacillary leprosy: A clinicopathological assessment. Indian J Dermatol Venereol Leprol 2005;71:242-5.
40. Rastogi N, Legrand E, Sola C. The mycobacteria: An introduction to nomenclature and pathogenesis. Rev Sci Tech 2001;20:21-54.
41. Reibel F, Cambau E, Aubry A. Update on the epidemiology, diagnosis, and treatment of leprosy. Med Mal Infect 2015;45:383-93.
42. Ren YR, Pan F, Parvez S, Fleig A, Chong CR, Xu J, et al. Clofazimine inhibits human Kv1. 3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS One 2008;3:e4009.
43. Rodrigues LC, Lockwood DN. Leprosy now: Epidemiology, progress, challenges, and research gaps. Lancet Infect Dis 2011;11:464-70.
44. Rook GA, Hamelmann E, Brunet LR. Mycobacteria and allergies. Immunobiology 2007;212:461-73.
45. Sarode G, Sarode S, Anand R, Patil S, Jafer M, Baeshen H, et al. Epidemiological aspects of leprosy. Dis Mon 2020;66:100899.
46. Scollard DM. Chemotherapy of leprosy has changed (almost) everything. Lepr Rev 2012;83:245-6.
47. Scollard DM. The biology of nerve injury in leprosy. Lepr Rev 2008;79:242-53.
48. Eichelmann K, Gonzalez SG, Salas-Alanis JC, Ocampo-Candiani J. Leprosy. An update: Definition, pathogenesis, classification, diagnosis, and treatment. Actas Dermosifiliogr 2013;104:554-63.
49. Worobec SM. Treatment of leprosy/Hansen’s disease in the early 21st century. Dermatol Ther 2009;22:518-37.
50. Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from North India1. Int J Lepr Other Mycobact Dis 2004;72:125-33.
51. Lastória JC, de Abreu MA. Leprosy: Review of the epidemiological, clinical, and etiopathogenic aspects-Part 1. An Bras Dermatol 2014;89:205-18.
52. Lockwood DN, Kumar B. Treatment of leprosy. BMJ 2004;328:1447-8.
53. Lockwood DN, Saunderson PR. Nerve damage in leprosy: A continuing challenge to scientists, clinicians and service providers. Int Health 2012;4:77-85.
54. Maymone MB, Venkatesh S, Laughter M, Abdat R, Hugh J, Dacso MM, et al. Leprosy: Treatment and management of complications. J Am Acad Dermatol 2020;83:17-30.
55. Monot M, Honoré N, Garnier T, Araoz R, Coppée JY, Lacroix C, et al. On the origin of leprosy. Science 2005;308:1040-2.
56. Moschella SL. An update on the diagnosis and treatment of leprosy. J Am Acad Dermatol 2004;51:417-26.
57. Mungroo MR, Khan NA, Siddiqui R. Mycobacterium leprae: Pathogenesis, diagnosis, and treatment options. Microb Pathog 2020;149:104475.
58. Naafs B. Leprosy after the year 2000. Trop Med Int Health 2000;5:400-3.
59. Narang T, Dogra S. Minocycline in leprosy patients with recent onset clinical nerve function impairment. Dermatol Ther 2017;30:e12404.
60. Kar HK, Gupta R. Treatment of leprosy. Clin Dermatol 2015;33:55-65.
61. Katoch VM. Advances in the diagnosis and treatment of leprosy. Expert Rev Mol Med 2002;4:1-14.
62. Ooi WW, Srinivasan J. Leprosy and the peripheral nervous system: Basic and clinical aspects. Muscle Nerve 2004;30:393-409.
63. Pai VV. Role of clofazimine in management of reactions in leprosy: A brief overview. Indian J Drugs Dermatol 2015;1:12.
64. Pai VV, Ganapati R, Rao R. Development and evolution of WHO MDT and newer treatment regimens. In: IAL Textbook of Leprosy. New Delhi: Jaypee Brothers Medical Publishers Pvt. Ltd.; 2010. p. 353-67.
65. Qi J, Virga KG, Das S, Zhao Y, Yun MK, White SW, et al. Synthesis of bi-substrate state mimics of dihydropteroate synthase as potential inhibitors and molecular probes. Bioorg Med Chem 2011;19:1298-305.
66. Rambukkana A. Molecular basis for the peripheral nerve predilection of Mycobacterium leprae. Curr Opin Microbiol 2001;4:21-7.
67. Rao PN, Jain S. Newer management options in leprosy. Indian J Dermatol 2013;58:6-11.
68. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev 2006;19:338-81.
69. Scollard DM, Stryjewska BM, Prestigiacomo JF, Gillis TP, Waguespack- LaBiche J. Hansen’s disease (leprosy) complicated by secondary mycobacterial infection. J Am Acad Dermatol 2011;64:593-6.
70. Sehgal VN, Sardana K, Dogra S. The imperatives of leprosy treatment in the pre-and post-global leprosy elimination era: Appraisal of changing the scenario to current status. J Dermatolog treat 2008;19:82-91.
71. Setia MS, Shinde SS, Jerajani HR, Boivin JF. Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and meta-analysis. Trop Med Int Health 2011;16:1541-51.
72. Simon M, Scherlock J, Duthie MS, de Jesus AR. Clinical, immunological, and genetic aspects in leprosy. Drug Dev Res 2011;72:509-27.
73. Swaminathan S, Rekha VB. Drugs used in tuberculosis and leprosy. In: Side Effects of Drugs Annual. Vol. 32. ???: ???; 2010. p. 555-69.
74. Talhari C, Talhari S, Penna GO. Clinical aspects of leprosy. Clin Dermatol 2015;33:26-37.
75. Tortoli E. The new mycobacteria: An update. FEMS Immunol Med Microbiol 2006;48:159-78.
76. Walker SL, Lockwood DN. Leprosy Type 1 (reversal) reactions and their management. Lepr Rev 2008;79:372-86.
77. White C, Franco-Paredes C. Leprosy in the 21st century. Clin Microbiol Rev 2015;28:80-94.
78. Wilder-Smith EP, van Brakel WH. Nerve damage in leprosy and its management. Nat Clin Pract Neurol 2008;4:656-63.
79. Mohanty PS, Bansal AK, Naaz F, Gupta UD, Dwivedi VD, Yadava U. Ribonucleotide reductase as a drug target against drug resistance Mycobacterium leprae: A molecular docking study. Infect Genet Evol 2018;60:58-65.
80. Maladan Y, Krismawati H, Hutapea HM, Oktavian A, Fatimah R. A new Mycobacterium leprae dihydropteroate synthase variant (V39I) from Papua, Indonesia. Heliyon 2019;5:e01279.
81. Ertas M, Sahin Z, Bulbul EF, Bender C, Biltekin SN, Berk B, et al. Potent ribonucleotide reductase inhibitors: Thiazole-containing thiosemicarbazone derivatives. Arch Pharm 2019;352:1900033.
82. Misko TA, Liu YT, Harris ME, Oleinick NL, Pink J, Lee HY, et al. Structure-guided design of anti-cancer ribonucleotide reductase inhibitors. J Enzyme Inhib Med Chem 2019;34:438-50.
83. Crona M, Codo P, Jonna VR, Hofer A, Fernandes AP, Tholander F. A ribonucleotide reductase inhibitor with deoxyribonucleoside-reversible cytotoxicity. Mol Oncol 2016;10:1375-86.
84. Nasr T, Bondock S, Ibrahim TM, Fayad W, Ibrahim AB, AbdelAziz NA, et al. New acrylamide-sulfisoxazole conjugates as dihydropteroate synthase inhibitors. Bioorg Med Chem 2020;28:115444.
85. Nasr T, Bondock S, Eid S. Design, synthesis, antimicrobial evaluation and molecular docking studies of some new thiophene, pyrazole and pyridone derivatives bearing sulfisoxazole moiety. Eur J Med Chem 2014;84:491-504.
86. Zhao Y, Shadrick WR, Wallace MJ, Wu Y, Griffith EC, Qi J, et al. Pterin-sulfa conjugates as dihydropteroate synthase inhibitors and antibacterial agents. Bioorg Med Chem Lett 2016;26:3950-4.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.